Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $205.0 million.

  • Foghorn Therapeutics' Liabilities and Shareholders Equity fell 3353.42% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $973.9 million, marking a year-over-year decrease of 1731.98%. This contributed to the annual value of $284.0 million for FY2024, which is 67.64% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Liabilities and Shareholders Equity stood at $205.0 million, which was down 3353.42% from $226.2 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $519.8 million for Q4 2021, and its period low was $186.1 million during Q3 2021.
  • For the 5-year period, Foghorn Therapeutics' Liabilities and Shareholders Equity averaged around $321.4 million, with its median value being $308.4 million (2024).
  • In the last 5 years, Foghorn Therapeutics' Liabilities and Shareholders Equity surged by 13321.03% in 2022 and then crashed by 3353.42% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Liabilities and Shareholders Equity stood at $519.8 million in 2021, then decreased by 22.1% to $404.9 million in 2022, then fell by 29.38% to $285.9 million in 2023, then fell by 0.68% to $284.0 million in 2024, then decreased by 27.83% to $205.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $205.0 million in Q3 2025, compared to $226.2 million in Q2 2025 and $258.7 million in Q1 2025.